Eli Lilly and Company (LLY)
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Lilly is set to acquire Centessa for up to $7.8B, adds sleep disorder drugs and advances its push to diversify beyond obesity and diabetes treatments.
Eli Lilly to acquire Centessa in $6.3B deal to expand neuroscience portfolio
Eli Lilly and Co $LLY said on Tuesday it will acquire Centessa Pharmaceuticals $CNTA for $38 per share in cash, with a potential contingent value right (CVR) worth up to $9 per share, valuing the deal at approximately $6.3 billion upfront and up to $7.8 billion including milestones. The acquisition adds Centessa's sleep-wake disorder pipeline, including its lead asset cleminorexton, to Lilly's neuroscience business.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Healthcare ETFs in Spotlight Amid Eli Lily's $2.8B AI Drug Move
Eli Lilly's $2.75B AI drug deal with Insilico spotlights healthcare ETFs as investors seek diversified exposure to the fast-growing AI-driven pharma space.
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership
Eli Lilly is doubling down on AI drug development with its latest deal.
Eli Lilly teams up with Insilico to accelerate AI-powered drug development
Eli Lilly and Co (NYSE:LLY) has entered into a drug discovery collaboration with Insilico Medicine, a clinical-stage biotechnology firm focused on generative artificial intelligence, to advance the development of new therapeutics across multiple disease areas, it was announced over the weekend. Under the agreement, Lilly will obtain an exclusive worldwide license to develop, manufacture and commercialize certain potentially best-in-class oral drug candidates that are currently in preclinical development.
Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery
Pharmaceutical titan Eli Lilly wants to bring medications developed with AI to market. To that end, the company has struck a $2.75 billion deal, announced Sunday (March 29), with Hong Kong-based Insilico Medicine.
Eli Lilly inks $2.75B AI deal with Insilico, bets on China biotech
Global pharmaceutical major Eli Lilly has signed a drug discovery agreement with Insilico Medicine that could be worth up to $2.75 billion. The deal underscores the growing role of artificial intelligence and China's biotech ecosystem in shaping the future of drug development.
Eli Lilly, InSilico Strike AI Drug Discovery Deal
Hong Kong-listed InSilico sad the deal could be valued at as much as $2.75 billion.
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023.
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
1 Reason Eli Lilly Stock Is Still a Buy
Eli Lilly boasts competitive margins by industry standards. Several initiatives could help the company improve on that front.
